Nevertheless, pharmaceutical companies have pursued the twincretin concept, developing GLP-1/GIP dual agonists such as tirzepatide, an analogue biased in favour of GIP over GLP-1 activity [55], and NNC0090-2746, another analogue with balanced GLP-1 and GIP activity [56]
10 Additionally, not all OSA patients are obese and therefore wouldnt benefit from GLP-1s
The research showed the gingerol group had a dramatic increase in GLP-1 production and improved glucose tolerance (9)
The rare serious side effects require awareness and physician monitoring
Journal of Clinical Medicine, 13 (21), 6336
Some interesting things happen when you think you're conducting a high-level study, is even participating in a study can change behavior